Pfizer has posted satisfactory growth in bottom line during the second quarter ended May 2010 with higher income from clinical development operations. Its net profit increased by 10.9 per cent to Rs 34.69 crore from Rs 31.29 crore in the corresponding period of last year. The company's net sales increased by 14.2 per cent to Rs 212.33 crore from Rs 185.85 crore. Its pharmaceutical division sales went up by 15.7 per cent to Rs 184.70 crore from Rs 159.60 crore and that of clinical development operations moved up sharply by 66.6 per cent to Rs 10.68 crore from Rs 6.41 crore. Its sales from animal health division increased by 5.3 per cent to RS 27.63 crore from Rs 26.25 crore.
Pfizer has amalgamated Duchem Laboratories Ltd with the company with effect from December 1, 2008. Thus the figures are not comparable. It's employees cost increased by 56.1 per cent to Rs 49.73 crore from Rs 31.86 crore during the same quarter of last year.
For the first half ended May 2010, Pfizer's net sales increased by 11.6 per cent to Rs 414.94 crore from Rs 371.82 crore in the similar period of last year, with pharmaceutical sales of Rs 357.34 crore as against Rs 317.92 crore, a growth of 12.4 per cent. Its sales from clinical development operations increased by 46.6 per cent to Rs 15.32 crore from Rs 10.45 crore and that of animal health products increased by 7 per cent to Rs 57.60 crore from Rs 53.84 crore.